Aluminum Zirconium Tetrachlorohydrex Gly

證據等級: L5

預測適應症: 0 個

Aluminum Zirconium Tetrachlorohydrex Gly: Cosmetic Antiperspirant Ingredient — No Repurposing Prediction Available

One-Sentence Summary

Aluminum Zirconium Tetrachlorohydrex Gly is an aluminum-zirconium complex widely used as an active antiperspirant ingredient in personal care products, primarily functioning by forming transient plugs in eccrine sweat ducts to mechanically reduce perspiration.

The TxGNN model did not generate any predicted new indications for this compound, and no pharmaceutical registrations were found in either Taiwan or US databases, meaning there is currently no evidence base to support a drug repurposing evaluation.

Quick Overview

Item	Content
Original Indication	Not registered as a pharmaceutical drug; used as a cosmetic/OTC antiperspirant ingredient
Predicted New Indication	None generated
TxGNN Prediction Score	N/A
Evidence Level	L5 (Model prediction only — no prediction produced)
US Market Status	Not marketed as a pharmaceutical drug
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Aluminum Zirconium Tetrachlorohydrex Gly (AZTG) is an inorganic aluminum-zirconium salt complex commonly formulated as a topically applied antiperspirant active. Its primary mode of action involves the formation of aluminum hydroxide gel plugs within the lumina of eccrine sweat ducts, thereby physically impeding sweat secretion to the skin surface. This mechanism is fundamentally physical/mechanical rather than systemic pharmacological, which limits its relevance as a candidate for systemic drug repurposing.

Unlike classical pharmaceutical actives that interact with specific molecular targets (receptors, enzymes, transporters), AZTG is classified under cosmetic regulations (e.g., US FDA OTC Antiperspirant monograph, 21 CFR Part 350) rather than as a New Drug Application product. It has no known systemic absorption profile of pharmacological relevance, no established pharmacokinetic parameters (Cmax, AUC, t½), and no known receptor-binding or enzyme-inhibition mechanism that could mechanistically anchor a repurposing hypothesis.

The absence of TxGNN predictions is therefore scientifically consistent: the knowledge graph underlying TxGNN is populated with pharmacologically active, systemically acting compounds cross-referenced against disease nodes via DrugBank, clinical trial data, and biomedical literature. A topically deposited inorganic salt complex with no systemic target interaction is unlikely to produce meaningful disease–drug associations within this framework.

Safety Considerations

Please refer to the package insert or cosmetic product safety data sheet for safety information. No pharmaceutical-grade DDI data, contraindication records, or regulatory warning texts were found in the queried sources.

Conclusion and Next Steps

Decision: Hold

Rationale: Aluminum Zirconium Tetrachlorohydrex Gly is a cosmetically regulated antiperspirant active ingredient with no pharmaceutical registrations, no systemic pharmacological mechanism, and no TxGNN-generated repurposing predictions. It does not currently meet the entry criteria for drug repurposing evaluation.

To proceed, the following is needed:

Confirm whether there is a specific pharmaceutical or therapeutic application hypothesis motivating this query (e.g., hyperhidrosis management, aluminum compound toxicology research, or an alternative salt form with systemic activity)
If a specific therapeutic hypothesis exists, a manual literature review of primary research (not TxGNN) should be conducted, as the compound falls outside the model’s coverage scope
Retrieve full DrugBank entry (DrugBank query returned 1 result per the query log) to confirm molecular target annotations, if any exist
Clarify regulatory pathway: if the intention is to develop a dermatological prescription product (e.g., for primary hyperhidrosis), an NDA/505(b)(2) pathway assessment is more appropriate than a repurposing analysis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.